[go: up one dir, main page]

MA32817B1 - Sels de l'ester du (1r*,2r*,4r*)-2-(2-{[3-(4,7dimethoxy-1h-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-5 - Google Patents

Sels de l'ester du (1r*,2r*,4r*)-2-(2-{[3-(4,7dimethoxy-1h-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-5

Info

Publication number
MA32817B1
MA32817B1 MA33872A MA33872A MA32817B1 MA 32817 B1 MA32817 B1 MA 32817B1 MA 33872 A MA33872 A MA 33872A MA 33872 A MA33872 A MA 33872A MA 32817 B1 MA32817 B1 MA 32817B1
Authority
MA
Morocco
Prior art keywords
imidazol
dimethoxy
benzo
propyl
amino
Prior art date
Application number
MA33872A
Other languages
Arabic (ar)
English (en)
Inventor
Stefan Abele
Stéphanie Combes
Jacques-Alexis Funel
Kurt Hilpert
Francis Hubler
Katharina Reichenbaecher
Dorte Renneberg
Raumer Markus Von
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41403088&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32817(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MA32817B1 publication Critical patent/MA32817B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES SELS CRISTALLINS DE L'ESTER DU (1R*,2R*,4R*)-2-(2-{[3-(4,7-DIMÉTHOXY-1H -BENZOIMIDAZOL-2-YL)- PROPYL]-MÉTHYL-AMINO}-ÉTHYL)-5-PHÉNYL -BICYCLO[2.2.2]OCT-5-ÈN-2-YLE DE L'ACIDE ISOBUTYRIQUE, DES PROCÉDÉS POUR LEUR PRÉPARATION, DES COMPOSITIONS PHARMACEUTIQUES CONTENANT LESDITS SELS CRISTALLINS, ET LEUR UTILISATION COMME MÉDICAMENTS, EN PARTICULIER COMME BLOQUEURS DE CANAUX CALCIQUES.
MA33872A 2008-10-22 2011-05-20 Sels de l'ester du (1r*,2r*,4r*)-2-(2-{[3-(4,7dimethoxy-1h-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-5 MA32817B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2008054351 2008-10-22
PCT/IB2009/054637 WO2010046857A1 (fr) 2008-10-22 2009-10-21 Sels de l’ester du (1r*,2r*,4r*)-2-(2-{[3-(4,7-diméthoxy-1h-benzoimidazol-2-yl)-propyl]-méthyl-amino}-éthyl)-5-phényl-bicyclo[2.2.2]oct-5-èn-2-yle de l’acide isobutyrique

Publications (1)

Publication Number Publication Date
MA32817B1 true MA32817B1 (fr) 2011-11-01

Family

ID=41403088

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33872A MA32817B1 (fr) 2008-10-22 2011-05-20 Sels de l'ester du (1r*,2r*,4r*)-2-(2-{[3-(4,7dimethoxy-1h-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-5

Country Status (22)

Country Link
US (1) US8492555B2 (fr)
EP (1) EP2344461B1 (fr)
JP (1) JP4913926B2 (fr)
KR (1) KR101331291B1 (fr)
CN (1) CN102186828B (fr)
AR (1) AR074049A1 (fr)
AU (1) AU2009306002B2 (fr)
BR (1) BRPI0920635B8 (fr)
CA (1) CA2740722C (fr)
CL (1) CL2011000921A1 (fr)
DK (1) DK2344461T3 (fr)
ES (1) ES2618178T3 (fr)
HU (1) HUE032044T2 (fr)
IL (1) IL212405A (fr)
MA (1) MA32817B1 (fr)
MX (1) MX342043B (fr)
MY (1) MY160597A (fr)
NZ (1) NZ592996A (fr)
RU (1) RU2516247C2 (fr)
TW (1) TWI463981B (fr)
WO (1) WO2010046857A1 (fr)
ZA (1) ZA201103734B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102186828B (zh) 2008-10-22 2014-07-16 埃科特莱茵药品有限公司 异丁酸(1r*,2r*,4r*)-2-(2-{[3-(4,7-二甲氧基-1h-苯并咪唑-2-基)-丙基]-甲基-胺基}-乙基)-5-苯基-二环[2.2.2]辛-5-烯-2-基酯的盐
KR101836552B1 (ko) * 2010-10-20 2018-03-08 아이도시아 파마수티컬즈 리미티드 바이시클로[2.2.2]옥탄-2-온 화합물의 부분입체선택적 제조

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US6268377B1 (en) * 1998-09-28 2001-07-31 Merck & Co., Inc. Method for treating androgen-related conditions
CA2462913A1 (fr) * 2001-10-10 2003-04-17 Aryx Therapeutics Composes a base de mibefradil en tant que bloqueurs de canaux calciques, utilises dans le traitement de l'hypertension et de l'angine
WO2008132679A1 (fr) * 2007-04-27 2008-11-06 Actelion Pharmaceuticals Ltd Composés pontés de cycles à six chaînons
BRPI0911538B1 (pt) 2008-04-25 2021-05-18 Idorsia Pharmaceuticals Ltd Composição farmacêutica contendo um composto derivado de benzimidazol e uso do composto
CN102186828B (zh) 2008-10-22 2014-07-16 埃科特莱茵药品有限公司 异丁酸(1r*,2r*,4r*)-2-(2-{[3-(4,7-二甲氧基-1h-苯并咪唑-2-基)-丙基]-甲基-胺基}-乙基)-5-苯基-二环[2.2.2]辛-5-烯-2-基酯的盐
US8314253B2 (en) 2008-10-22 2012-11-20 Actelion Pharmaceuticals Ltd. Bridged tetrahydronaphthalene derivatives
WO2010046729A2 (fr) 2008-10-23 2010-04-29 Actelion Pharmaceuticals Ltd Composés tétrahydronaphthalène

Also Published As

Publication number Publication date
US20110263667A1 (en) 2011-10-27
ZA201103734B (en) 2015-12-23
RU2011120042A (ru) 2012-11-27
MX342043B (es) 2016-09-12
WO2010046857A1 (fr) 2010-04-29
US8492555B2 (en) 2013-07-23
ES2618178T3 (es) 2017-06-21
MY160597A (en) 2017-03-15
AR074049A1 (es) 2010-12-22
KR20110075030A (ko) 2011-07-05
KR101331291B1 (ko) 2013-11-22
CA2740722A1 (fr) 2010-04-29
TWI463981B (zh) 2014-12-11
CN102186828B (zh) 2014-07-16
BRPI0920635A2 (pt) 2018-03-13
AU2009306002B2 (en) 2015-01-15
NZ592996A (en) 2013-01-25
MX2011004138A (es) 2011-07-20
BRPI0920635B8 (pt) 2021-05-25
EP2344461B1 (fr) 2016-12-14
EP2344461A1 (fr) 2011-07-20
IL212405A (en) 2016-05-31
DK2344461T3 (en) 2017-02-13
IL212405A0 (en) 2011-06-30
JP2012506416A (ja) 2012-03-15
CA2740722C (fr) 2017-08-22
TW201021796A (en) 2010-06-16
AU2009306002A1 (en) 2010-04-29
CN102186828A (zh) 2011-09-14
HUE032044T2 (en) 2017-08-28
RU2516247C2 (ru) 2014-05-20
CL2011000921A1 (es) 2011-11-11
BRPI0920635B1 (pt) 2021-02-23
JP4913926B2 (ja) 2012-04-11

Similar Documents

Publication Publication Date Title
BRPI0911254A2 (pt) processo para a preparação de um composto
EP2350054A4 (fr) Dérivés d'azétidine comme inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
MA32977B1 (fr) Formes polymorphiques du (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo(c(1,2)oxaborol-1-ol
BRPI0905147A8 (pt) processo para síntese de ivabradina e seus sais de adição com um ácido farmaceuticamente aceitável
EP2124872A4 (fr) Compositions pour améliorer des conditions cutanées renfermant de l'alpha-bisabolol en tant que principe actif
BR112012007869A2 (pt) "processo de síntese de um derivado de fórmula e composto"
EP2591105A4 (fr) Procédés et compositions pour l'inhibition spécifique de bêta-caténine par arn double brin
EP2318314A4 (fr) Synthèse d'un silico-alumino-phosphate cristallin
EA201101147A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
EP2196460A4 (fr) Composé de sel d'acide sulfonique d'un dérivé de 4-carbamoyl-5-hydroxyimidazole
BRPI0914531A2 (pt) "método para a preparação de um polimorfo a"
EA201000398A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
EP2276479A4 (fr) Promédicaments d'inhibiteurs de la neuraminidase
BR112012009611A2 (pt) ''processo para a preparação de um composto de fómula (i)''
IL216202A0 (en) PROCESS FOR THE PREPARATION OF A COMPOUND USEFUL AS AN INHIBITOR OF TAFIa
BRPI0914400A2 (pt) "processo para a síntese de um composto"
EA201200498A1 (ru) Новый способ синтеза ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
MX2010009926A (es) Nuevo proceso para la preparacion de derivados de acido ciclohexancarboxilico.
SV2011003923A (es) 3-aminociclopentancarboxamidas
MA32817B1 (fr) Sels de l'ester du (1r*,2r*,4r*)-2-(2-{[3-(4,7dimethoxy-1h-benzoimidazol-2-yl)-propyl]-methyl-amino}-ethyl)-5
BRPI1012007A2 (pt) "método para a preparação de ácido 2-ceto-carboxílico"
BRPI0811380A2 (pt) "processo para a preparação de ácido carboxílico purificado"
EA201000397A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
BRPI0716691A2 (pt) "processo para produzir um composto de Ácido bifosfânico"
JO2812B1 (en) A method of obtaining the aggregate V crystal form of agomelatine